Literature DB >> 19403847

Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumor confined to the rectal wall?

Raphaëla C Dresen1, Geerard L Beets, Harm J T Rutten, Sanne M E Engelen, Max J Lahaye, Roy F A Vliegen, Adriaan P de Bruïne, Alfons G H Kessels, Guido Lammering, Regina G H Beets-Tan.   

Abstract

PURPOSE: To retrospectively assess accuracy of magnetic resonance (MR) imaging after radiation therapy with concomitant chemotherapy for downsizing of the primary lesion to ypT0-2 tumor confined to rectal wall in locally advanced rectal cancer, with histopathologic findings as reference standard, and to evaluate additional value of volumetric analysis.
MATERIALS AND METHODS: The institutional review board approved the study and waived informed consent. Sixty-seven patients met criteria of the study. T2-weighted MR images obtained before and after radiation therapy with concomitant chemotherapy were assessed for tumor stage by expert abdominal radiologist, colorectal surgeon, and general radiologist. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated; tumor volume was measured (compared with Mann-Whitney U test). Findings were correlated with histopathologic findings.
RESULTS: Sixty-seven patients (38 men, 29 women; mean age, 63 years) who underwent radiation therapy with concomitant chemotherapy and surgery (all but one) were evaluated. The PPV for prediction of tumor confined to rectal wall (ypT0-2) was 91% (10 of 11), 86% (six of seven), and 88% (seven of eight) for expert abdominal radiologist, surgeon, and general radiologist, respectively. In 24 patients, sensitivity was 42% (10), 25% (six), and 29% (seven). ypT0-2 tumors had significantly smaller volumes than did ypT3-4 tumors before radiation therapy with concomitant chemotherapy (55 vs 92 cm(3), P = .038). Volume reduction rates were significantly higher in ypT0-2 than in ypT3-4 tumors (89% vs 61%, P < .001). If volume before radiation therapy with concomitant chemotherapy was 50 cm(3) or smaller and volume reduction rate was 75% or higher, excised tumor was always confined to rectal wall (ypT0-2). By using these criteria, 43% (six of 14) of cases with overstaging could have been predicted to be ypT0-2 tumors correctly.
CONCLUSION: Downsizing to ypT0-2 tumors can be accurately predicted by combining morphologic tumor staging predictions with results from volumetric analyses. MR images obtained after radiation therapy with concomitant chemotherapy might be helpful in more individualized treatment planning. (c) RSNA, 2009.

Entities:  

Mesh:

Year:  2009        PMID: 19403847     DOI: 10.1148/radiol.2521081200

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  39 in total

1.  T2 weighted signal intensity evolution may predict pathological complete response after treatment for rectal cancer.

Authors:  Ewelina Kluza; Esther D Rozeboom; Monique Maas; Milou Martens; Doenja M J Lambregts; Jos Slenter; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2012-07-10       Impact factor: 5.315

2.  A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.

Authors:  Julio Garcia-Aguilar; Qian Shi; Charles R Thomas; Emily Chan; Peter Cataldo; Jorge Marcet; David Medich; Alessio Pigazzi; Samuel Oommen; Mitchell C Posner
Journal:  Ann Surg Oncol       Date:  2011-07-14       Impact factor: 5.344

3.  Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer.

Authors:  Seung Ho Kim; Jae Young Lee; Jeong Min Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2010-10-27       Impact factor: 5.315

4.  Locally advanced rectal cancer: is diffusion weighted MRI helpful for the identification of complete responders (ypT0N0) after neoadjuvant chemoradiation therapy?

Authors:  S Sassen; M de Booij; M Sosef; R Berendsen; G Lammering; R Clarijs; M Bakker; R Beets-Tan; F Warmerdam; R Vliegen
Journal:  Eur Radiol       Date:  2013-07-06       Impact factor: 5.315

5.  Is there a benefit in using magnetic resonance imaging in the prediction of preoperative neoadjuvant therapy response in locally advanced rectal cancer?

Authors:  Lian-Ming Wu; Jiong Zhu; Jiani Hu; Yan Yin; Hai-Yan Gu; Jia Hua; Jie Chen; Jian-Rong Xu
Journal:  Int J Colorectal Dis       Date:  2013-03-21       Impact factor: 2.571

6.  Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging.

Authors:  I Song; S H Kim; S J Lee; J Y Choi; M J Kim; H Rhim
Journal:  Br J Radiol       Date:  2011-02-22       Impact factor: 3.039

7.  DCE-MRI time-intensity curve visual inspection to assess pathological response after neoadjuvant therapy in locally advanced rectal cancer.

Authors:  Antonella Petrillo; Roberta Fusco; Mario Petrillo; Vincenza Granata; Francesco Bianco; Massimiliano Di Marzo; Paolo Delrio; Fabiana Tatangelo; Gerardo Botti; Biagio Pecori; Antonio Avallone
Journal:  Jpn J Radiol       Date:  2018-07-23       Impact factor: 2.374

Review 8.  Advances and challenges in treatment of locally advanced rectal cancer.

Authors:  J Joshua Smith; Julio Garcia-Aguilar
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 9.  Volumetric analysis at abdominal CT: oncologic and non-oncologic applications.

Authors:  Virginia B Planz; Meghan G Lubner; Perry J Pickhardt
Journal:  Br J Radiol       Date:  2018-11-30       Impact factor: 3.039

10.  Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients. A low-field MRI study.

Authors:  M P Schmid; B Mansmann; M Federico; J C A Dimopoulous; P Georg; E Fidarova; W Dörr; R Pötter
Journal:  Strahlenther Onkol       Date:  2013-01-25       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.